As we mark three years since the start of the large-scale Russian invasion of Ukraine, I believe it is timely to take stock ...

Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Entrada Therapeutics Inc (TRDA – Research Report), ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy - - Follows recently received ...

Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...

Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received ...

New rivalries, fresh faces, line-up changes and much more. Gear up for Buriram as MotoGP blasts back into action ...

Despite having far fewer soldiers and resources, Ukraine has resisted for three years, making a mockery of the predictions ...

The 15-year-old festival will be held Feb. 27 through March 1 at Megaplex Theatres Sunset in St. George at 8:30 p.m.